Cargando…
Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
Background: The most effective symptomatic treatment in Parkinson’s disease (PD) is levodopa in standard doses. However, as the disease progresses, there may be a need for a more personalized approach and fine tuning, in accordance with the patients’ needs. This study aims to evaluate the individual...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400411/ https://www.ncbi.nlm.nih.gov/pubmed/34442364 http://dx.doi.org/10.3390/jpm11080720 |
_version_ | 1783745308666101760 |
---|---|
author | Grétarsdóttir, Helga María Widman, Erik Johansson, Anders Nyholm, Dag |
author_facet | Grétarsdóttir, Helga María Widman, Erik Johansson, Anders Nyholm, Dag |
author_sort | Grétarsdóttir, Helga María |
collection | PubMed |
description | Background: The most effective symptomatic treatment in Parkinson’s disease (PD) is levodopa in standard doses. However, as the disease progresses, there may be a need for a more personalized approach and fine tuning, in accordance with the patients’ needs. This study aims to evaluate the individual experience of levodopa/carbidopa 5/1.25 mg microtablets (LC-5) in clinical practice with respect to efficacy, tolerability, and usability. The method used was as follows: patients answered a questionnaire concerning the effect and usability of LC-5, and their medical records were reviewed. Regarding results, thirty-five survey responses were obtained, and 29 patients’ medical records were reviewed. The LC-5 dose dispenser usability was generally rated positively and facilitated medication adherence. The majority (85%) of patients reported symptom improvement while using LC-5, compared with previous standard treatments. These results suggest that LC-5 therapy is generally well-tolerated, with favorable patient-reported efficacy and user friendliness, as well as the possibility for an individualized, fine-tuned PD treatment. Further studies with a prospective design and larger study population are needed to confirm the results. |
format | Online Article Text |
id | pubmed-8400411 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84004112021-08-29 Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice Grétarsdóttir, Helga María Widman, Erik Johansson, Anders Nyholm, Dag J Pers Med Article Background: The most effective symptomatic treatment in Parkinson’s disease (PD) is levodopa in standard doses. However, as the disease progresses, there may be a need for a more personalized approach and fine tuning, in accordance with the patients’ needs. This study aims to evaluate the individual experience of levodopa/carbidopa 5/1.25 mg microtablets (LC-5) in clinical practice with respect to efficacy, tolerability, and usability. The method used was as follows: patients answered a questionnaire concerning the effect and usability of LC-5, and their medical records were reviewed. Regarding results, thirty-five survey responses were obtained, and 29 patients’ medical records were reviewed. The LC-5 dose dispenser usability was generally rated positively and facilitated medication adherence. The majority (85%) of patients reported symptom improvement while using LC-5, compared with previous standard treatments. These results suggest that LC-5 therapy is generally well-tolerated, with favorable patient-reported efficacy and user friendliness, as well as the possibility for an individualized, fine-tuned PD treatment. Further studies with a prospective design and larger study population are needed to confirm the results. MDPI 2021-07-26 /pmc/articles/PMC8400411/ /pubmed/34442364 http://dx.doi.org/10.3390/jpm11080720 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Grétarsdóttir, Helga María Widman, Erik Johansson, Anders Nyholm, Dag Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice |
title | Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice |
title_full | Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice |
title_fullStr | Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice |
title_full_unstemmed | Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice |
title_short | Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice |
title_sort | personalized medicine approach in treating parkinson’s disease, using oral administration of levodopa/carbidopa microtablets in clinical practice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400411/ https://www.ncbi.nlm.nih.gov/pubmed/34442364 http://dx.doi.org/10.3390/jpm11080720 |
work_keys_str_mv | AT gretarsdottirhelgamaria personalizedmedicineapproachintreatingparkinsonsdiseaseusingoraladministrationoflevodopacarbidopamicrotabletsinclinicalpractice AT widmanerik personalizedmedicineapproachintreatingparkinsonsdiseaseusingoraladministrationoflevodopacarbidopamicrotabletsinclinicalpractice AT johanssonanders personalizedmedicineapproachintreatingparkinsonsdiseaseusingoraladministrationoflevodopacarbidopamicrotabletsinclinicalpractice AT nyholmdag personalizedmedicineapproachintreatingparkinsonsdiseaseusingoraladministrationoflevodopacarbidopamicrotabletsinclinicalpractice |